The U.S. FDA approved Ropivacaine for neurological disorders on September 26, 1996. Ropivacaine is a local anesthetic with an active ingredient called Ropivacaine. It belongs to the class of medicine called an amide.

Ropivacaine is a medication used to numb a specific area of the body, preventing pain signals from reaching the brain and providing temporary pain relief during medical procedures or surgeries.

Ropivacaine will be administered to you by a healthcare professional in a hospital setting. The part of the body where it will be used will depend on why you are being given. Do not self-administer. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.

The most common side effects of Ropivacaine are sleepiness, trouble concentrating, dry mouth, dizziness, increase in appetite, drowsiness, and headache. Serious side effects while taking Ropivacaine are shortness of breath, wheezing, swelling of face, lips, tongue, or other parts of the body, and rash.

Do not take Ropivacaine if you are allergic to Ropivacaine, other amide-type local anesthetics, or any of its ingredients. Avoid using this medicine during intravenous regional anesthesia or obstetric paracervical anesthesia.  Do not use this medicine if you are diagnosed with hypovolemia, where a decrease in blood volume could result in a drop in blood pressure.

Before starting the treatment, inform your physician if you have been using Ropivacaine, and exercise caution against direct blood vessel injections to prevent immediate toxicity. Avoid injecting inflamed areas. Inform your doctor of age-related health concerns, heart problems, advanced liver or severe kidney issues, or acute porphyria. Adjustments to the Ropivacaine Altan dose may be necessary based on these conditions. If you or your family has a history of porphyria, alternate anesthetic methods might be considered. This medicine should cautiously used in premature infants, newborns, and children under 12, as its effects and suitable injections for these groups are not well understood. Report to your doctor if you are on a salt-controlled diet before taking the injection.

Liver and kidney patients should take Ropivacaine cautiously and inform their doctor about all the underlying medical conditions. Do not stop the medicine until your doctor advises. Unless your doctor advises, do not breastfeed while taking this injection. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information. 

Follow the prescribed dosage and administration instructions provided by your healthcare professional. Inform your doctor about any known allergies or medical conditions you have before receiving Ropivacaine. If you notice any unexpected or severe side effects, such as difficulty breathing or an allergic reaction, seek immediate medical attention. Inform your healthcare professional about any other medications or supplements you are consuming to avoid potential drug interactions. If you have any concerns regarding the treatment, consult your healthcare professional for information.

1. Boehringer Ingelheim International GmbH, Electronic medicines compendium (emc), [Revised on Feb 2023] [Accessed 22nd August 2023], pil.5073.pdf (medicines.org.uk)
2. Boehringer Ingelheim Pharmaceuticals, Inc., US Food and Drug Administration, [ Revised on Oct 2015] [ Accessed on 22nd August 2023], PRAXBIND (Ropivacaine) injection, for intravenous use (fda.gov)
3. James L. Zehnder, Drugs Used in Disorders of Coagulation, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 608-625.

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.